The in vitro pharmacology of LY IGlar (LY2963016): a new insulin glargine product

被引：0
|
作者：
Moyers, J. S. [1 ]
Kahl, S. D. [1 ]
Ruan, X. [1 ]
Zhang, C. [1 ]
Farmen, M. W. [1 ]
Michael, M. D. [1 ]
Owens, R. A. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
519
引用
收藏
页码：S255 / S255
页数：1
相关论文
共 50 条
  • [21] COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 INSULIN GLARGINE PRODUCTS, LY2963016 AND LANTUS®, IN HEALTHY SUBJECTS AT 2 DOSE LEVELS
    Zhang, X.
    Lam, E. C. Q.
    Seger, M.
    Coutant, D.
    Chua, L. Y.
    Tan, L. H.
    Soon, D.
    Linnebjerg, H.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S264 - S264
  • [22] Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with type 1 diabetes mellitus: the ELEMENT 1 study
    Pollom, R. K.
    Blevins, T.
    Dahl, D.
    Rosenstock, J.
    Huster, W. J.
    Ilag, L. L.
    Prince, M. J.
    [J]. DIABETOLOGIA, 2014, 57 : S69 - S69
  • [23] Authors' Reply to Dr. Riccardo Perfetti: "LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes"
    Lamb, Yvette N.
    Syed, Yahiya Y.
    [J]. BIODRUGS, 2018, 32 (02) : 179 - 179
  • [24] Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study
    Blevins, T. C.
    Dahl, D.
    Rosenstock, J.
    Ilag, L. L.
    Huster, W. J.
    Zielonka, J. S.
    Pollom, R. K.
    Prince, M. J.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (08): : 726 - 733
  • [25] Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM or T2DM
    Deeg, Mark
    Ilag, Liza
    Huster, William J.
    Pollom, Robyn K.
    Zielonka, Jason
    Prince, Melvin J.
    Konrad, Robert J.
    [J]. DIABETES, 2014, 63 : A19 - A19
  • [26] Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study
    Blevins, Thomas
    Dahl, Dominik
    Rosenstock, Julio
    Ilag, Liza
    Huster, William J.
    Pollom, Robyn K.
    Prince, Melvin J.
    [J]. DIABETES, 2014, 63 : A19 - A19
  • [27] Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T2DM: The ELEMENT 2 Study
    Rosenstock, Julio
    Hollander, Priscilla
    Bhargava, Anuj
    Ilag, Liza
    Pollom, Robyn K.
    Huster, William J.
    Prince, Melvin J.
    [J]. DIABETES, 2014, 63 : A17 - A17
  • [28] The efficacy and safety of LY2963016 among patients with Type 1 and Type 2 diabetes previously treated with insulin glargine
    Asaro-Harris, A.
    Dahl, D.
    Lacaya, L. B.
    Pollom, R. K.
    Ilag, L. L.
    Zielonka, J. S.
    Hadjiyanni, I.
    [J]. DIABETIC MEDICINE, 2015, 32 : 168 - 168
  • [29] Comparative Pharmacokinetics and Pharmacodynamics of Two Insulin Glargine Products, LY2963016 and Lantus®, in Healthy Subjects at Two Dose Levels
    Zhang, Xin
    Lam, Eric Chen Quin
    Seger, Mary E.
    Coutant, David
    Chua, Laiyi
    Tan, Lai Hock
    Soon, Danny
    Linnebjerg, Helle
    [J]. DIABETES, 2014, 63 : A227 - A228
  • [30] Authors’ Reply to Dr. Riccardo Perfetti: “LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes”
    Yvette N. Lamb
    Yahiya Y. Syed
    [J]. BioDrugs, 2018, 32 : 179 - 179
12345